Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eisai To Shut Down H3 In Global R&D Restructuring

New Structure From October; New Astellas W Coast Campus

Executive Summary

Eisai has decided to shut down its US oncology research operation H3 by September in the course of restructuring its global R&D organization. The majority of H3 employees will be laid off as Eisai Inc. and new organization DHBL absorb its functions and assets. Meanwhile another Japanese pharma firm, Astellas, builds up its US R&D footprint.

You may also be interested in...



Kyorin Pharma To Shut Down US Subsidiary ActivX

Kyorin Pharma is to end operations at its US subsidiary ActivX 18 years since its acquisition. Although the California firm’s kinase-probing technology has contributed to Kyorin’s R&D, the Japanese firm acknowledged limits to future applicability in the development of candidate compounds.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: BMS’s new products meet early expectations; Eisai to shut a US unit in global R&D restructuring; Roche aims high for Vabysmo; US priority review for Biogen’s ALS contender; and a chat with Gennova’s CEO.

Eisai/Biogen’s Lecanemab Faces Smoother Passage Through US FDA Than Aducanumb

With amyloid plaque reduction established as a surrogate endpoint by Aduhelm’s accelerated approval for Alzheimer’s disease, lecanemab is unlikely to face an advisory committee before its 6 January user fee goal date.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel